MLYS
Healthcare BiotechnologyMineralys Therapeutics, Inc.
$23.63
-0.51 -2.11% today
Price History
Not enough data
Key Stats
Market Cap
2.09B
Avg Volume
1.04M
EPS
-$4.22
52W High
$47.65
52W Low
$22.30
Div. Yield
0.0%
Analyst Ratings
Buy0
Str Buy
9
Buy
1
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-9.45
P/B Ratio
3.79
EV/EBITDA
-4.11
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(80.9%)
Return on Assets
(46.2%)
Liquidity & Leverage
Current Ratio
34.46
Quick Ratio
34.24
Debt / Equity
0.18
Total Cash
661.41M
Total Debt
97.62M
About
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
mineralystx.com